19 May 2013
Keywords: vernalis, v1003, performs, well, pain, study, uk-based
Article | 20 March 2006
UK-based pharmaceutical company Vernalis says that a Phase IIa study of its developmental intranasal formulation of buprenorphine, V1003, used
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 August 2006
17 May 2013
© 2013 thepharmaletter.com